HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Grazoprevir

HCID 44603531
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
1350462-55-3
Standard SMILES
C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)O[C@@H]1C[C@H]1CCCCCc1nc3ccc(OC)cc3nc1O2)C(=O)NS(=O)(=O)C1CC1
InChIKey
OBMNJSNZOWALQB-NCQNOWPTSA-N
Molecular formula
C38H50N6O9S
Average molar mass
766.9 g/mol
Monoisotopic mass
766.33599837

Overview

Grazoprevir is an azamacrocyclic compound that is a hepatitis C protease inhibitor used in combination with elbasvir (under the brand name Zepatier) for treatment of chronic HCV genotypes 1 or 4 infection in adults. It has a role as an antiviral drug, a hepatoprotective agent and a hepatitis C protease inhibitor. It is a carbamate ester, a lactam, an aromatic ether, a quinoxaline derivative, a member of cyclopropanes, an azamacrocycle and a N-sulfonylcarboxamide.

Names & identifiers

Preferred name
Grazoprevir
IUPAC
(1R,18R,20R,24S,27S)-24-tert-butyl-N-[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamide
English name
MK 5172 hydrate
Molecular formula
C38H50N6O9S.H2O
Molecular weight
784.91868

Names & synonyms

Grazoprevir1350514-68-9MK5172MK-5172 ANHYDROUS(1R,18R,20R,24S,27S)-24-tert-butyl-N-[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo[24.2.1.03,12.05,10.018,20]nonacosa-3,5(10),6,8,11-pentaene-27-carboxamideCHEBI:132975DTXSID50159234MK-5172 MONOHYDRATEDTXSID00159229grazoprevirum(1R,18R,20R,24S,27S)-24-tert-butyl-N-((1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl)-7-methoxy-22,25-dioxo-2,21-dioxa-4,11,23,26-tetrazapentacyclo(24.2.1.03,12.05,10.018,20)nonacosa-3,5(10),6,8,11-pentaene-27-carboxamideRefChem:782705
Show more names
AnapivirMK5172 hydrateMK 5172 hydrateMK-5172 (hydrate)Grazoprevir hydrate (MK-5172 hydrate)MK5172 HYDRATEMK 5172 HYDRATE(33R,35S,91R,92R,5S)-5-(tert-butyl)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphane-35-carboxamide Hydrate

Properties

Computed structural properties

XLogP
4.7
Topological polar surface area
204 Ų
Hydrogen bond donors
3
Hydrogen bond acceptors
11
Rotatable bonds
8
Heavy atoms
54
Formal charge
0
Complexity
1,580

Experimental & physicochemical properties

DrugsPharmaceuticals -> Listed in ZINC15
Human Drugs · 3 items

Breast Feeding; Lactation; Milk, Human; Antiviral Agents; Protease Inhibitors

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Physicochemical properties

storage temp.
-20 °C · Store at -20°C
solubility
50 mg/mL · DMSO : 50 mg/mL (63.70 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble)
form
Powder
color
White to off-white
FDA UNII
4 O2AB118LA · 4O2AB118LA
Symbol(GHS)
8 · GHS08
Signal word
Warning
Hazard statements
373 · H373
Precautionary statements
260 · P260-P314-P501

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H373 (100%): May causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]

P260, P319, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 35 reports by companies from 1 notifications to the ECHA C&L Inventory.

Hazard information

Hazard Classes and CategoriesSTOT RE 2 (100%)

Toxicology

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

Signal word
Warning
Symbol(GHS)
GHS08
Hazard statements
H373
Precautionary statements
P260-P314-P501

Chemistry & industry

Pharmacology

ATC Code · 2 items

J - Antiinfectives for systemic use

QJ - Antiinfectives for systemic use

Protein BindingGrazoprevir is more than 98.8% bound to plasma proteins. It binds both human serum albumin and α1-acid glycoprotein.
PharmacodynamicsGrazoprevir is classified as a direct-acting antiviral (DAA) and prevents viral replication in HCV genotypes 1a, 1b, and 4.
Mechanism of Action · 1 item

Grazoprevir is a second generation NS3/4a protease inhibitor used to inhibit viral HCV replication. NS3/4a protease is an integral part of viral replication and mediates the cleavage the virally encoded polyprotein to mature proteins (NS3, NS4A, NS4B, NS5A and NS5B). Grazoprevir inhibits the NS3/4protease enzymes of HCV genotype 1a, 1B, and 4 with IC50 values of 7pM, 4pM, and 62pM, respectively.

Biological Half-LifeThe geometric mean apparent terminal half-life for Grazoprevir is 31 hours in HCV-infected subjects.
Metabolism/MetabolitesGrazoprevir is partially eliminated by oxidative metabolism meditated by CYP3A. No circulating metabolites of have been detected in human plasma.
FDA Pharmacological Classification · 6 items

8YE81R1X1J

GRAZOPREVIR ANHYDROUS

Mechanisms of Action [MoA] - HCV NS3/4A Protease Inhibitors

Established Pharmacologic Class [EPC] - Hepatitis C Virus NS3/4A Protease Inhibitor

Mechanisms of Action [MoA] - Breast Cancer Resistance Protein Inhibitors

Mechanisms of Action [MoA] - Cytochrome P450 3A Inhibitors

MeSH Pharmacological Classification · 1 item

Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.

Related reactions

2 records
New reaction record
HRID 659832 reaction equation
HRID 659832As product
HRID 1008859 reaction equation
HRID 1008859As product

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Cyclopropanecarboxamide, N-[[[(1R,2R)-2-[5-(3-hydroxy-6-methoxy-2-quinoxalinyl)pentyl]cyclopropyl]oxy]carbonyl]-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-, cyclic (1→2)-ether, hydrate (1:1), (1R,2S)-
(1aR,5S,8S,10R,22aR)-N-[(R-1R,2S)-1-[(cyclopropylsulfonamido)carbonyl]-2-ethenylcyclopropyl]-14-methoxy-5-(2-methylpropan-2-yl)-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide hydrate
DTXCID4081725DTXCID9081720J05AP11Cyclopropanecarboxamide, N-((((1R,2R)-2-(5-(3-hydroxy-6-methoxy-2-quinoxalinyl)pentyl)cyclopropyl)oxy)carbonyl)-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-, cyclic (1->2)-ether, hydrate (1:1) (1R,2S)-1350462-55-34O2AB118LAGrazoprevir HydrateGrazoprevir monohydrate

Database identifiers

CAS
1350462-55-3、1350514-68-9
PubChem CID
44603531
DTXSID
DTXSID50159234
ChEMBL
CHEMBL2063090、CHEMBL3039533
ChEBI
CHEBI:132975
UNII
8YE81R1X1J
EC Number
808-306-3
Nikkaji
J3.213.950G
Absorption, Distribution and Excretion · 4 items

Grazoprevir reaches peak plasma concentration 0.5-3 hours after administration. Grazoprevir has an absolute bioavailability of 27%. When taken with food the peak concentration of Grazoprevir increases 2.8 fold but this increase in exposure has not been deemed clinically relevant.

Grazoprevir is mainly eliminated in the feces (90%) with very little eliminated in the urine (<1%).

Grazoprevir has an estimated apparent volume of distribution of 1250 liters. It is thought to distribute primarily to the liver with its uptake facilitated by organic anion transporting polypeptide 1B1/3.

The clearance of Grazoprevir has not been determined.

Applications · 1 item

UsesGrazoprevir hydrate (MK-5172 hydrate) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively[1][2]. Grazoprevir hydrate inhibits SARS-CoV-2 3CLpro activity[3].